Detrusitol/Detrusitol SR

Overactive bladder w/ symptoms of urinary urgency, frequency or urge incontinence.

Detrusitol Adult including elderly 2 mg bd, may be reduced to 2 mg once daily based on individual tolerability. Total daily dose: 4 mg. Patient receiving potent CYP3A4 inhibitors, renal & hepatic impairment 1 mg bd. Total daily dose: 2 mg. Detrusitol SR 4 mg once daily, may be decreased to 2 mg once daily depending on response & tolerability. Mild to moderate hepatic or severe renal impairment 2 mg once daily.

May be taken with or without food. Detrusitol SR: Swallow whole.

Hypersensitivity to tolterodine tartrate, fesoterodine fumarate. Urinary retention, uncontrolled narrow-angle glaucoma. Detrusitol Myasthenia gravis, severe ulcerative colitis, toxic megacolon. Detrusitol SR Gastric retention.

Patients w/ significant bladder outlet obstruction at risk of urinary retention; GI obstructive disorders eg, pyloric stenosis; autonomic neuropathy; hiatus hernia; risk for decreased GI motility or patients being treated for narrow-angle glaucoma. History of congenital or documented acquired QT prolongation. Concomitant use w/ drugs prolonging QT interval including class IA & III antiarrhythmics. May affect ability to drive & use machines. Not recommended in renal & severe hepatic impairment. Not recommended during pregnancy. Avoid use during lactation. Childn. Detrusitol Electrolyte disturbances eg, hypokalaemia, hypomagnesaemia, hypocalcaemia; bradycardia, relevant preexisting cardiac diseases eg, cardiomyopathy, myocardial ischaemia, arrhythmia, CHF. Patients on low Na diet. Avoid concomitant use w/ potent CYP3A4 inhibitors. Detrusitol SR Discontinue use if difficulty in breathing, upper airway obstruction or fall in BP & anticholinergic CNS effects occur. Patients at risk of gastric retention.

Headache; dry mouth. Dizziness; constipation, abdominal pain, dyspepsia; abnormal vision including abnormal accommodation; somnolence; dysuria. Detrusitol Bronchitis; paresthesia; dry eyes; vertigo; palpitations; flatulence, vomiting, diarrhoea; dry skin, urinary retention; fatigue, chest pain, peripheral oedema; increased wt. Detrusitol SR Fatigue; dizziness; xerophthalmia; anxiety; sinusitis.

Increased serum conc w/ potent CYP3A4 inhibitors eg, macrolids, antifungals, antiproteases. Detrusitol Reduced therapeutic effect w/ muscarinic cholinergic receptor agonists. Decreased effect of prokinetics eg, metoclopramide, cisapride. Detrusitol SR Increased AUC w/ fluoxetine. Increased frequency &/or severity of dry mouth, constipation, blurred vision, somnolence & other anticholinergic pharmacological effects w/ other anticholinergic/antimuscarinic agents.

Drugs for Bladder & Prostate Disorders

G04BD07 - tolterodine ; Belongs to the class of urinary antispasmodics.

C